Principal Investigator: Sheema Chawla, MD
Title: Impact of timing of post-mastectomy radiation therapy and breast reconstruction: physician-reported complications and aesthetic results, and patient-reported outcomes
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
Principal Investigator: Sheema Chawla, MD
Title: Tailor RT: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
ClinicalTrials.gov Link: NCT03488693
Principal Investigator: Khusraw Sabit, MD
Title: Intra-Operative Radiation Therapy (IORT) Using the IntraBeam® System – A Registry Protocol
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
Principal Investigator: Farhan Imran, MD
Title: A Randomized, Open-label, Phase 3 Study of Adjuvant Sacituzumab Govitecan and Pembrolizumab Versus Treatment of Physician’s Choice in Patients with Triple Negative Breast Cancer who have Residual Invasive Disease after Surgery and Neoadjuvant Therapy
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
ClinicalTrials.gov Link: NCT05633654
Principal Investigator: Saad Jamshed, MD
Title: Observational Registry Collecting Data on Patients Diagnosed with Multiple Myeloma
Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital
Status: Accruing
Principal Investigator: Peter Kouides, MD
Title: URMC Collection of Specimens and Epidemiological and Clinical Outcomes Data in Patients with Hematological Malignancies
Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital
Status: Accruing
Principal Investigator: Saad Jamshed, MD
Title: A Post-Authorization Safety Study to Evaluate the Incidence of and Risk Factors for Severe and Fatal Infusion-related Reactions in Participants Treated with Daratumumab (Intravenous or Subcutaneous)
Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital
Status: Accruing
Principal Investigator: Saad Jamshed, MD
Title: Secondary Immunodeficiency (SID) Registry for Chronic Lymphocytic Leukemia, Lymphoma, and Multiple Myeloma
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
Principal Investigator: Saad Jamshed, MD
Title: A Phase 3, Two-Stage, Randomized, Multicenter, Open-Label Study Comparing Mezigdomide (CC-92480), Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Subjects with Relapsed or Refractory Multiple Myeloma (RRMM)
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
ClinicalTrials.gov Link: NCT05519085
Principal Investigator: Saad Jamshed, MD
Title: Phase 3 Study of Daratumumab/rHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients with Multiple Myeloma (MM) using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC)
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
ClinicalTrials.gov Link: NCT04071457
Principal Investigator: Greg Connolly, MD
Title: A Multicenter, Randomized, Open-Label, Blinded Endpoint Evaluation, Phase 3 Study Comparing the Effect of Abelacimab Relative to Apixaban on Venous Thromboembolism (VTE) Recurrence and Bleeding in Patients with Cancer Associated VTE
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
ClinicalTrials.gov Link: NCT05171049
QOL Lung Cancer Study
Principal Investigator: Sheema Chawla, MD
Title: Identifying Quality of Life (QOL) and Distress in Lung Cancer Patients and Evaluating Their Prognosis as it Relates to QOL and Distress
Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital
Status: Accruing
Principal Investigator: Mehul Patel, MD
Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
Clinical Trials.gov Link: NCT02194738
Principal Investigator: Mehul Patel, MD
Title: Integration of Immunotherapy into Adjuvant Therapy for Resected Non-Small Cell Lung Cancer: ALCHEMIST CHEMO-IO (ACCIO)
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
Principal Investigator: Mehul Patel, MD
Title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein
Locations: Rochester General Hospital and Linden Oaks
Status: Accruing
ClinicalTrials.gov Link: NCT02201992
Principal Investigator: Mehul Patel, MD
Title: Phase IV Observational Study to Collect Safety and Outcome Data in Real-World Setting in Adult Patients with Extensive Stage Small Cell Lung Cancer (SCLC) Receiving Zepzelca
Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital
Status: Accruing
ClinicalTrials.gov Link: NCT04894591
Principal Investigator: Jayashri Bhaskar, MD
Title: Clinical Utility of Management of Patients with CT and LDCT Identified Pulmonary Nodules Using the Percepta Nasal Swab Classifier – with Familiarization
Locations: Rochester General Hospital
Status: Accruing
Principal Investigator: Amy Bodrog, MD
Title: A Randomized Phase II Double-Blind Study of Olaparib versus Placebo Following Curative Intent Therapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital
Status:Accruing
ClinicalTrials.gov Link: NCT04858334
Principal Investigator: Mohammad Talal Khan, DO
Title: Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital
Status: Accruing
ClinicalTrials.gov Link: NCT05174169
Principal Investigator: Peter Bushunow, MD
Title: Study of Patient Experiences with Psychosocial Distress Screening at the Lipson Cancer Institute
Locations: Rochester General Hospital, Linden Oaks, and Unity Hospital
Status: Accruing
Lipson Cancer Institute – Rochester General Hospital
1425 Portland Avenue
Rochester, NY 14621
Lipson Cancer Institute – Linden Oaks
20 Hagen Drive
Suite 100
Rochester, NY 14625
Lipson Cancer Institute – Unity Hospital
1561 Long Pond Road
Suite 120
Rochester, NY 14626
Lipson Cancer Institute Clinical Research
Phone: 585-922-4020
